Thesis (Ph.D.). / Title from title page of PDF (viewed 2008/01/30). Written for the Dept. of Medicine, Division of Experimental Medicine. Includes bibliographical references.

Thesis (M.S.)--University of Tennessee Health Science Center, 2009. / Title from title page screen (viewed on August 5, 2009). Research advisor: David A. Tipton, D.D.S., Ph.D. Document formatted into pages (vi, 39 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 27-38).

Thesis (Ph. D.)--University of Oklahoma. / Bibliography: leaves 164-207.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / O cÃncer colorretal(CCR) à altamente prevalente nos paÃses mais ricos e industrializados. As metaloproteinases de matriz (MMPs) sÃo importantes enzimas que facilitam a invasÃo e disseminaÃÃo do tumor em vÃrios tipos de cÃncer, inclusive o colorretal. Os inibidores teciduais de metaloproteinases (TIMPs) sÃo os principais inativadores fisiolÃgicos destas enzimas. Este estudo avaliou a expressÃo de metaloproteinase-2 (MMP-2), metaloproteinase-14 (MMP-14) e inibidor tecidual de metaloproteinases-2 (TIMP-2) no cÃncer colorretal. O imunomarcador CD68 foi utilizado para caracterizar a natureza das cÃlulas mononucleadas do estroma. Amostras teciduais de 50 casos de colectomias, devido ao cÃncer colorretal no perÃodo de 2004 a 2010, obtidas dos arquivos do Departamento de Patologia e Medicina Legal (DPML), Faculdade de Medicina da Universidade Federal do Cearà (UFC), foram analisadas. Realizou-se tissue microarrays e a seguir imuno-histoquÃmica para avaliar a expressÃo de MMP-2, MMP-14 e TIMP-2 de acordo com os seguintes escores baseados em outros relatos: 0= sem imunomarcaÃÃo ou raras cÃlulas marcadas (<5%); 1 = discreta marcaÃÃo na maioria (> 50%) das cÃlulas tumorais ou cÃlulas mononucleares do estroma, ou moderada marcaÃÃo em uma minoria de cÃlulas (<50 %); 2 =marcaÃÃo moderada na maioria (> 50%) de cÃlulas tumorais ou cÃlulas mononucleares ou intensa marcaÃÃo em minoria de cÃlulas (<50%); 3 = marcaÃÃo intensa na maioria (> 50%) de cÃlulas tumorais ou cÃlulas mononucleares. Observou-se relaÃÃo entre a expressÃo aumentada de MMP-14 em mononucleares de tumor primÃrio e casos sem metÃstases linfonodais (MMP-14, escores 2 e 3/N0 : 23/24 = 95%; N1-N3: 14/20 = 70%, p = 0,0353). No entanto, nenhuma relaÃÃo significativa foi encontrada entre a expressÃo de MMP-14, MMP-2 e TIMP-2 nos tumores primÃrios em cÃlulas cancerosas ou mononucleares e outros parÃmetros clÃnico-patolÃgicos. A imunoexpressÃo de MMP-2 foi negativa nas cÃlulas neoplÃsicas, em tumores primÃrios (47/47=100%) e metastÃticos (12/12 = 100%). A imunorreatividade de MMP-14 em cÃlulas neoplÃsicas foi frequentemente positiva em tumores primÃrios (50/50 = 100%) e metastÃticos (7/8= 88%). Em mononucleares, a maioria dos quais macrÃfagos (corados pelo CD68), a expressÃo positiva de MMP-14 tambÃm predominou marcadamente, tanto em tumores primÃrios (46/47 = 98%) como em carcinomas metastÃticos (9/10 = 90%). A expressÃo de TIMP-2 em cÃlulas neoplÃsicas, discreta, ocorreu em 70% de tumores primÃrios (35/50 casos) e 100% dos metastÃticos (8/8). A imunocoloraÃÃo para TIMP-2 em macrÃfagos associados ao tumor (TAMs) foi ainda mais elevada do que nas cÃlulas neoplÃsicas. Em conclusÃo, a MMP-14 e TIMP-2 sÃo frequentemente expressas em carcinomas colo-retais em ambas localizaÃÃes anatÃmicas, principalmente nas metÃstases para linfonodos , sugerindo que estas proteases desempenham papel importante na invasÃo local e na progressÃo tumoral neste tipo de cÃncer. A predominÃncia destes marcadores nas cÃlulas mononucleares (sobretudo macrÃfagos) , claramente evidentes na positividade para a MMP-2, enfatiza a importÃncia do microambiente tumoral no desenvolvimento de neoplasias. / The colorectal cancer (RCC) is highly prevalent in richer and industrialized countries. The matrix metalloproteinases (MMPs) are regarded as important for facilitating tumor invasion and spread in various cancers, including colorectal. Tissue inhibitors of metalloproteinases (TIMPs) are the major physiological inhibitors of MMPs. The expression of metalloproteinase-2 (MMP-2), metalloproteinase 14 (MMP-14) and tissue inhibitor of metalloproteinases-2 ( TIMP-2) in colorectal cancer was assessed. CD68 immunostaininig was utilized to the characterization of mononuclear cells nature. Paraffin-embedded tissues from patients undergoing colectomy for colorectal cancer in the period 2004 to 2010, were selected from the files of the Department of Pathology and Forensic Medicine (DPML), Medical School , Federal University of Cearà (UFC). Tissue microarrays were performed and slides were obtained for immunohistochemical detection of the expression of MMP-2, MMP-14 and TIMP-2 and the tissue samples analyzed. The following scores were applied: 0 = no immunostaining or rare labeled cells (<5%), 1 = slight marking the majority (> 50%) of tumor cells or stromal mononuclear cells, or moderate marking in a minority of cells (<50%) 2 = moderate labeling in the majority (> 50%) of tumor or mononuclear cells or intense marking in the minority of cells (<50%) and 3 = intense labeling in the majority (> 50%) of tumor cells or mononuclear cells. In this study, the relationship between increased expression of MMP-14 in mononuclear primary tumor cells and cases without lymph node metastases (MMP-14, 2 and 3/N0 scores: 23/26 = 88%; N1-N3: 14/21 = 67%, p = 0.0353) was stablished . However, no significant relationship was found between the immunohistochemical expression of MMP-14, MMP-2 and TIMP-2 in primary tumors in cancer cells and mononuclear cells and other clinico-pathological parameters. The expression of MMP-2 were negative in the neoplastic cells both in primary tumors (47/47 = 100%) and in metastatic ones (12/12 = 100%). The immunoreactivity of MMP-14 in neoplastic cells in primary tumors was positive (50/50 = 100%) and in all cases except one of metastatic carcinoma (7/8 = 88%). In mononuclear cells, most of them characterized as macrophages (CD68 stained), MMP-14 positive expression also predominated markedly, both in primary tumors (46/47 = 98%) and in metastatic carcinomas (9/10 = 90%). TIMP-2 expression in neoplastic cells of primary tumors occurred in 35/50 cases (70%) and lymph nodes showed positive immunostaining in all cases (8/8 = 100%). In both sites there were no cases with high expression. The TIMP-2 immunoreactivity in tumour associated macrophages (TAMs) was even higher than in the neoplastic cells. In conclusion, MMP-14 and TIMP-2 are frequently expressed in colorectal carcinomas in both anatomical sites , mainly in lymph node metastasis, suggesting that these proteases play an important role in local invasion and tumor progression of these cancers. The predominance of these biomarkers in mononuclear cells, clearly evident in the positivity for MMP-2, emphasizes the importance of tumor microenvironment in the development of neoplasms.

Abstract The invasion of a tumour through tissue limiting basement membranes is the critical step in malignant growth. Gelatinases (MMP-2 and MMP-9) are endopeptidases capable of degrading extracellular and pericellular matrix proteins such as collagen IV, the major component of basement membranes. An over-expression of these gelatinases is generally found in malignant tumours and is linked to impaired prognosis in many cancer types. Tissue inhibitors of metalloproteinases (TIMPs), endogenous regulators of the MMP activity, have recently been introduced as multifunctional proteins, which have paradoxical roles in tumour growth. Little data exists on the clinical significance of the gelatinases and TIMPs in gynaecological cancers. In this study the clinical significance of the gelatinases was studied in endometrial and uterine cervical cancers by using immunohistochemical staining with specific antibodies. In epithelial ovarian cancer (EOC) these enzymes and their TIMPs were studied in the preoperative serum samples using ELISA assay. Additionally, sequential serum measurements were performed during chemotherapy to evaluate them as treatment response indicators. In endometrial cancer, MMP-9 positivity correlated to a poor histological differentiation and an advanced clinical stage. High MMP-2 expression correlated to a poor differentiation, and unfavourable survival in stage I cancers, with mortality rates of 5% and 19% in patients with MMP-2 negative versus intensively MMP-2 positive tumours, respectively. In cervical cancers high MMP-2 expression correlated to an increased mortality risk. High MMP-9 expression was connected to a good differentiation of a tumour. In EOC, a high circulating TIMP-1 value correlated to all the examined aggressive features of EOC, including poor survival. The serum measurements of TIMP-1 were uninformative about response evaluation during chemotherapy but paradoxically, an increase in gelatinases and TIMP-2 seemed to reflect a good response to treatment. In conclusion, the data from this study show that high MMP-2 expression in tumour tissue could be prognostic in endometrial and cervical cancer, and preoperative circulating TIMP-1 could serve as an additional prognostic marker in EOC. Studies with larger patient cohorts would be necessary to further explore the value of these enzymes in clinical practice in gynaecological cancers.

Metaloproteinases (MMP) são enzimas proteolíticas, fundamentais à carcinogênese. Evoluções de 37 pacientes operados por carcinomas medulares da tireóide foram comparadas com dados clinicopatológicos e expressões imuno-histoquímicas de MMP-2, MT1-MMP e TIMP-2 em seus espécimes neoplásicos. Condições clínicas finais foram correlacionadas com os aspectos clinicopatológicos: exame físico cervical positivo, sintomas sistêmicos, diâmetro tumoral, extensão neoplásica para a cápsula tireóidea, extensão tumoral para tecidos adjacentes, invasão vascular, metástases cervicais, estádio TNM, evidências de doenças cervical e/ou a distância. Expressões de MMP-2 e MT1-MMP foram correlacionadas à evolução clínica e maior proporção de TIMP-2, em relação à MMP-2, correlacionou-se a benefícios prognósticos / Metalloproteinases (MMP) are proteolytic enzymes, fundamental to carcinogenesis. Outcome of 37 patients operated on due to medullary thyroid carcinomas were compared to clinicopathologic data and immunohistochemistry expression of MMP-2, MT1-MMP and TIMP-2 in their neoplastic specimens. Final clinical conditions were related to the clinicopathologic aspects: clinical features, systemic symptoms, tumor size, tumor extension to thyroid capsule, tumor extension to adjacent tissues, vascular invasion, cervical metastases, TNM stage and evidences of disease in the neck and/or distant metastases. Expression of MMP-2 and MT1-MMP were related to outcome and greater proportion of TIMP-2, over MMP-2, was related to prognostic benefits

Metaloproteinases (MMP) são enzimas proteolíticas, fundamentais à carcinogênese. Evoluções de 37 pacientes operados por carcinomas medulares da tireóide foram comparadas com dados clinicopatológicos e expressões imuno-histoquímicas de MMP-2, MT1-MMP e TIMP-2 em seus espécimes neoplásicos. Condições clínicas finais foram correlacionadas com os aspectos clinicopatológicos: exame físico cervical positivo, sintomas sistêmicos, diâmetro tumoral, extensão neoplásica para a cápsula tireóidea, extensão tumoral para tecidos adjacentes, invasão vascular, metástases cervicais, estádio TNM, evidências de doenças cervical e/ou a distância. Expressões de MMP-2 e MT1-MMP foram correlacionadas à evolução clínica e maior proporção de TIMP-2, em relação à MMP-2, correlacionou-se a benefícios prognósticos / Metalloproteinases (MMP) are proteolytic enzymes, fundamental to carcinogenesis. Outcome of 37 patients operated on due to medullary thyroid carcinomas were compared to clinicopathologic data and immunohistochemistry expression of MMP-2, MT1-MMP and TIMP-2 in their neoplastic specimens. Final clinical conditions were related to the clinicopathologic aspects: clinical features, systemic symptoms, tumor size, tumor extension to thyroid capsule, tumor extension to adjacent tissues, vascular invasion, cervical metastases, TNM stage and evidences of disease in the neck and/or distant metastases. Expression of MMP-2 and MT1-MMP were related to outcome and greater proportion of TIMP-2, over MMP-2, was related to prognostic benefits

Abstract Lymphomas are a heterogeneous group of malignancies, which usually have a good prognosis and high cure rates. Lymphomas are sensitive to chemotherapy and radiotherapy, and many patients can be cured even after a relapse, resulting in a need for effective follow-up. However, the cost-benefit ratio of radiological imaging in predicting the forthcoming relapses is poor. Consequently, there is a need for biological prognostic and predictive markers to distinguish patients at the highest risk of relapse at the time of diagnosis or during follow-up. Despite rapid progress in lymphoma treatments, some patients still die from lymphoma. Thus, more data on the basic biological features of lymphomas are also needed. Gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) have been found to play a role in the progression of solid tumours. TP53 is a tumour suppressor gene, the mutations and protein over-expression of which have been demonstrated to be associated with survival in most cancer types. There is also some evidence that these proteins could have prognostic significance in lymphomas as well. In the present study, the tissue expression, plasma concentrations and clinical value of gelatinases and their tissue inhibitors were evaluated in lymphomas. 249 primary tissue samples from patients with Hodgkin, follicular, or diffuse large B-cell lymphoma were analysed for expression of gelatinases and/or their inhibitors using immunohistochemistry. In follicular lymphoma, p53 protein expression was also investigated. The plasma samples of 126 lymphoma patients and a control group of 44 healthy volunteers were collected and studied by ELISA. TIMP-1 expression correlated with bulky tumour and nodular sclerosis subtype of Hodgkin lymphoma. In follicular lymphoma, p53 over-expression was an independent adverse prognostic factor for survival and a predictor of histological transformation. Plasma MMP-2-TIMP-2 complex appeared to be a potential follow-up marker predicting the risk of relapse in lymphoma patients. Plasma levels of the MMP-2-TIMP-2 complex, proMMP-2, TIMP-2 and proMMP-2/TIMP-2 ratio were at abnormal levels both in patients with newly diagnosed lymphoma and those in remission compared to healthy controls. The clinical significance of these markers needs further studies.

No description available.

Os tumores hipofisários mesmo sendo, em sua maioria, benignos, podem apresentar comportamento invasivo, com extensão para seio cavernoso, seio esfenoidal e clivo. As metaloproteinases de matriz tipo 2 (MMP-2) e 9 (MMP-9) e o inibidor tecidual de metaloproteinases-2 (TIMP-2) têm sido estudados em relação ao comportamento invasivo desses tumores, em especial quanto à invasão do seio cavernoso. Esse estudo teve como objetivo avaliar a expressão proteica das MMP-2, MMP-9 e do TIMP-2 nos tumores hipofisários e sua relação com invasão do seio cavernoso e, de maneira inédita, investigar a expressão dessas proteínas em nível plasmático. Adicionalmente, foram avaliadas a expressão dos RNAs mensageiros (RNAm) das MMP-2 e TIMP-2 com intuito de correlacioná-las com a expressão proteica no tecido tumoral, bem como a expressão do marcador de proliferação Ki67. Foram selecionados 77 casos, todos com amostras de tumor emblocado em parafina para análise imuno-histoquímica (IHQ). Destes, foram coletadas amostras de tumor fresco em 29 pacientes e de sangue periférico pré-operatório em outros 29 casos. A expressão proteica plasmática foi detectada de forma semi-quantitativa utilizando um arranjo de anticorpos em membrana comercial. A expressão dos RNAm das MMP-2 e TIMP-2 foi avaliada por reação em cadeia da polimerase quantitativo (qPCR) em tempo real. Do total de casos, 20 pacientes apresentavam tumores com invasão para o seio cavernoso. A expressão proteica tumoral das MMP-2, MMP-9 e TIMP-2 apresentou-se aumentada no grupo invasivo, contudo esta diferença não foi estatisticamente significante em relação ao grupo não- invasivo. A expressão plasmática das MMP-9 e TIMP-2 também não mostrou diferença entre os dois grupos e não se correlacionou com a expressão tumoral. A expressão plasmática da MMP-2 não foi detectada em nenhum caso. Quanto à expressão do RNAm das MMP-2 e TIMP-2, também não houve diferença significante entre os grupos e nem correlação com a expressão proteica tecidual ou plasmática. Foi observada uma diferença significante na dimensão tumoral [3.6 (2.5-5.2) x 2.0 (1.3-2.7); P < 0.001] e no índice do Ki67 [1.05 (0.27-25) x 0.5 (0.2-1.0); P < 0.001] entre os grupos invasivo e não-invasivo respectivamente. Em conclusão, em nossa coorte, não foi encontrada relação entre a expressão tecidual e plasmática das MMP-2, MMP-9 e TIMP-2 e a invasão para o seio cavernoso nos adenomas hipofisários / Pituitary tumors, although mostly benign, may present invasive behavior, with extension to the cavernous sinus, sphenoid sinus and clivus. Type 2 (MMP-2) and type 9 (MMP-9) matrix metalloproteinases and the metalloproteinase tissue inhibitor type 2 (TIMP-2) have been studied in relation to the invasive behavior of these tumors, especially regarding invasion of the cavernous sinus. The aim of this study was to evaluate the protein expression of MMP-2, MMP-9 and TIMP-2 in pituitary tumors and its relation with invasion of the cavernous sinus and, in an unprecedented way, to investigate the expression of these proteins at the plasma level. Additionally, expression of MMP-2 and TIMP-2 messenger RNAs (mRNAs) was evaluated in order to correlate with protein expression in tumor tissue, as well as Ki67 proliferation marker expression. A total of 77 cases were selected, all of them with paraffin embedded tumor samples for immunohistochemical analysis (IHC). Of these, fresh tumor samples were collected in 29 patients and preoperative peripheral blood in another 29 cases. Protein plasma expression was detected semi-quantitatively using a commercial membrane antibody array. Expression of MMP-2 and TIMP-2 mRNAs was evaluated by quantitative realtime polymerase chain reaction (qPCR). Of the total cases, 20 patients presented tumors invasive to the cavernous sinus. Tumor protein expression of MMP-2, MMP-9 and TIMP-2 was increased in the invasive group, not reaching, however, statistically significant difference as compared with the non-invasive group. Plasma expression of MMP-9 and TIMP-2 also did not differ between the two groups and did not correlate with tumor expression. Plasma expression of MMP-2 was not detected in any case. Concerning MMP-2 and TIMP-2 mRNA expression, there was also no significant difference between groups and no correlation with tissue or plasma protein expression was observed. A significant difference was observed in tumor size [3.6 (2.5-5.2) x 2.0 (1.3-2.7); P < 0.001] and in the Ki67 index [1.05 (0.27-25) x 0.5 (0.2-1.0); P < 0.001] between the invasive and non-invasive groups respectively. In conclusion, in our cohort, no relationship was found between the tissue and plasma expression of MMP-2, MMP-9 and TIMP-2 and the invasion of the cavernous sinus in pituitary adenomas